Compare MINISO Group Holding Ltd (MNSO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? MINISO Group Holding Ltd trades at $12.69 (market cap $3.87B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: MINISO Group Holding Ltd pays a 5.21% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MINISO Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| MNSO | XBI | |
|---|---|---|
Market Cap | $3.87B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $26.63 | $164.28 |
52-Week Low | $11.30 | $85.16 |
Enterprise Value | $4.54B | — |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating EPS estimates with $0.591 versus $0.238 expected, and announced a HK$2 billion share repurchase program on June 29, 2026 (PRNewsWire). Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 13.02, indicating reasonable valuation.
The outlook is positive with projected revenue growth to $22.7 billion in 2026 and net profit doubling to $2.0 billion. However, risks include margin compression from rising expenses and mixed earnings history with two recent misses. Analyst consensus is 75% buy, but competitive pressures in retail remain a concern for sustained profitability.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
